Rheumatoid Arthritis News
Arthritis News: Golimumab Receives FDA Approval
New Onset Psoriasis may be Increased in TNF Inhibitor User
Mechanisms of the Atheroprotective Effect of Methotrexate Studied
Rituximab Non-responders do not Benefit from Repeated Treatments
The efficacy of rituximab, a monoclonal antibody directed against CD20 positive B cells, has been demonstrated for the treatment of rheumatoid arthritis (RA) in a number of key studies. However, not all patients respond to therapy. Whether patients with initial non-response may benefit from follow-up treatments (i.e. initial treatment resistance) has not been investigated.
PAD-4 Autoantibodies Identified as a Novel Severity Factor in RA
Antibodies against citrullinated proteins have emerged as powerful diagnostic and prognostic tools in RA that may contribute to the initiation phases of the disease. The enzymes that catalyze the citrullination process, known as peptidyl argenine deiminases (or PADs), may also be involved in the initiation and propagation steps of the RA disease process. Additionally, autoimmunity to these catalysts may identify a subset of RA patients with unique disease phenotypes.